FLYTE ACTIVATES HIGH-FREQUENCY BELMONT STAKES FLIGHT PROGRAM, DEPLOYING FLEET TO CAPTURE TRIPLE CROWN DEMAND
Rhea-AI Summary
Flyte, a subsidiary of Catheter Precision (NASDAQ:VTAK), is deploying its Cirrus Vision Jet fleet across the Northeast for the Belmont Stakes at Saratoga Race Course on June 6, 2026. The high-frequency, short-haul program targets dense, time-sensitive Triple Crown travel demand.
Key routes include NYC (HPN/TEB), East Hampton, and Boston (BED) to Saratoga Springs, with same-day inbound and outbound rotations, group and shared-cabin options, and operations flown by FAA Part 135 carrier Ponderosa Air.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: BJDX up 192.63%, while AEMD and AMIX are down 5.00% and 3.61%. With VTAK’s own intraday direction not specified, it is unclear whether this news-driven move aligns with a broader sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 18 | Earnings and acquisition | Positive | +9.1% | Q1 2026 revenue up 200% with Flyte acquisition boosting growth profile. |
| May 12 | Event-driven flight program | Positive | +9.7% | High-frequency Preakness Stakes flights targeting premium, time-sensitive travelers. |
| May 04 | Capacity and hiring push | Positive | -1.1% | Flyte boosted capacity and hiring after Spirit shutdown to capture displaced demand. |
| Apr 23 | Clinical data presentation | Positive | -1.9% | New VIVO and LockeT clinical data and HRS meeting presence highlighted technology. |
| Apr 21 | IP and patent update | Positive | -2.6% | USPTO allowance on LockeT technology supporting IP protection and growth strategy. |
Recent Flyte- and growth-focused announcements often read positively but have produced mixed reactions, with two clear upside moves and three instances where seemingly positive news was followed by share price declines.
Over the last few months, VTAK combined its core electrophysiology business with the Flyte aviation platform. On May 18, Q1 2026 results and the Flyte acquisition coincided with a 9.07% gain. Earlier in May, Flyte’s high-frequency Preakness program saw a 9.69% rise. However, other positive updates—capacity expansion and hiring on May 4, new clinical data on April 23, and a patent allowance on April 21—were followed by modest declines, underscoring inconsistent reactions to constructive news.
Market Pulse Summary
This announcement highlights Flyte’s strategy of targeting concentrated, high-value travel windows, using high-frequency short-haul flights to capture Belmont Stakes demand on June 6, 2026. It extends earlier event-driven deployments and underscores VTAK’s dual focus on cardiac devices and regional air mobility. When assessing this news, investors would typically watch subsequent updates on Flyte’s utilization, revenue contribution, and how aviation growth interacts with the company’s core electrophysiology business and existing financial constraints.
Key Terms
cardiac arrhythmias medical
faa-certified part 135 regulatory
AI-generated analysis. Not financial advice.
Flyte’s regional mobilization aims to capitalize on one of the most lucrative single-weekend surges in elite sports tourism
NEW YORK, NY, June 02, 2026 (GLOBE NEWSWIRE) -- – Flyte, a regional air mobility company focused on making private aviation more accessible and flexible for modern travelers, today announced the deployment of aircraft across the Northeast in anticipation of the Belmont Stakes at Saratoga Race Course in New York, on Saturday, June 6, 2026. This initiative aims to position the Company to capture one of the most concentrated and high-value travel weekends in U.S. horse racing.
As the final leg of the Triple Crown, Belmont Stakes draws national attention and a dense concentration of high-net-worth individuals, corporate hospitality groups, and time-sensitive travelers. This surge routinely gridlocks Northeast travel corridors, turning a standard drive into a lengthy, congested commute. Flyte’s operating model is designed to capture this demand through high-frequency, short-haul service connecting key Northeast markets to Saratoga Springs.
“Events like the Belmont highlight the scalability of our model,” said Marc Sellouk, CEO of Flyte. “When demand density, timing, and geography align, our ability to deploy aircraft and capture revenue in real time becomes a significant advantage.”
Key routes driving volume include:
- NYC (HPN / TEB) → Saratoga Springs
- East Hampton → Saratoga Springs
- Boston (BED) → Saratoga Springs
Flyte operates aircraft strategically staged across the northeast corridor, operating dense rapid-cycle flight operations structured around same-day inbound and outbound travel. The company has continuous aircraft rotations across key markets, offers group and shared-cabin bookings, and excels at handling concentrated weekend demand windows.
ABOUT FLYTE
Flyte is a technology-enabled regional air mobility subsidiary of Catheter Precision, Inc. operating a growing fleet of Cirrus Vision Jets. Focused on short-haul markets, Flyte provides a faster and more efficient alternative to traditional private charter travel. Flight operations are conducted through Flyte’s wholly owned subsidiary, Ponderosa Air, LLC, an FAA-certified Part 135 air carrier. With active operations and ongoing fleet expansion, Flyte is building a scalable aviation platform designed to serve underserved regional markets.
For more information, visit www.flyflyte.com.
ABOUT CATHETER PRECISION
Catheter Precision is an innovative U.S.-based medical device company developing advanced solutions to improve the treatment of cardiac arrhythmias. The Company focuses on bringing new technologies to market through physician collaboration and continuous product innovation.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding future plans, expectations, and projections, are forward-looking and subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “seek,” or similar expressions. These statements include, but are not limited to, expectations regarding growth, utilization, market share, customer behavior, and expansion initiatives. These and other risks are detailed in the Company’s filings with the Securities and Exchange Commission, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements except as required by law.
CONTACTS Investor Relations 973-691-2000 IR@catheterprecision.com Media Relations Flyte@elev8newmedia.com